CN112807328B - Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury - Google Patents
Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury Download PDFInfo
- Publication number
- CN112807328B CN112807328B CN202110219055.1A CN202110219055A CN112807328B CN 112807328 B CN112807328 B CN 112807328B CN 202110219055 A CN202110219055 A CN 202110219055A CN 112807328 B CN112807328 B CN 112807328B
- Authority
- CN
- China
- Prior art keywords
- selenium
- liver
- radiation
- powder
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000005855 radiation Effects 0.000 title claims abstract description 127
- 239000011669 selenium Substances 0.000 title claims abstract description 88
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 81
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 80
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 72
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 239000006041 probiotic Substances 0.000 title claims abstract description 23
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 210000004185 liver Anatomy 0.000 claims abstract description 130
- 230000009467 reduction Effects 0.000 claims abstract description 21
- 230000006378 damage Effects 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 122
- 229940091258 selenium supplement Drugs 0.000 claims description 68
- 230000001580 bacterial effect Effects 0.000 claims description 54
- 241001608472 Bifidobacterium longum Species 0.000 claims description 46
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 46
- 241000894006 Bacteria Species 0.000 claims description 38
- 230000037396 body weight Effects 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 12
- 238000004321 preservation Methods 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 229960001471 sodium selenite Drugs 0.000 claims description 5
- 235000015921 sodium selenite Nutrition 0.000 claims description 5
- 239000011781 sodium selenite Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 229940040526 anhydrous sodium acetate Drugs 0.000 claims description 4
- 235000015278 beef Nutrition 0.000 claims description 4
- 230000036542 oxidative stress Effects 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 230000000529 probiotic effect Effects 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 3
- 229960005055 sodium ascorbate Drugs 0.000 claims description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 3
- 125000003748 selenium group Chemical group *[Se]* 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 25
- 230000005865 ionizing radiation Effects 0.000 abstract description 15
- 238000010172 mouse model Methods 0.000 abstract description 6
- 208000030159 metabolic disease Diseases 0.000 abstract description 3
- 210000000056 organ Anatomy 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 83
- 241000699666 Mus <mouse, genus> Species 0.000 description 52
- 230000000694 effects Effects 0.000 description 42
- 230000002159 abnormal effect Effects 0.000 description 22
- 230000008859 change Effects 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 18
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 13
- 229940118019 malondialdehyde Drugs 0.000 description 13
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 230000002285 radioactive effect Effects 0.000 description 11
- 102000003777 Interleukin-1 beta Human genes 0.000 description 9
- 108090000193 Interleukin-1 beta Proteins 0.000 description 9
- 102000003814 Interleukin-10 Human genes 0.000 description 9
- 108090000174 Interleukin-10 Proteins 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 230000003449 preventive effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000006851 antioxidant defense Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 210000004279 orbit Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000004531 Selenoprotein P Human genes 0.000 description 2
- 108010042443 Selenoprotein P Proteins 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 2
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical group NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 229960001097 amifostine Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- -1 glycerol) Chemical class 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 231100000567 intoxicating Toxicity 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000718 radiation-protective agent Substances 0.000 description 1
- 229940124553 radioprotectant Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides application of selenium-rich probiotics in preparation of a medicine for treating and/or preventing radiation liver injury, and belongs to the field of biological medicines. According to the invention, the 3Gy X-ray radiation is utilized to induce the radiation liver injury mouse model, and the selenium-rich probiotics are administered through long-term intragastric administration, so that the selenium-rich probiotics can relieve the reduction of the weight and the liver index of the radiation liver injury mouse induced by the X-ray radiation, the increase of the related serum index level and the injury of related organs, and a new thought is provided for preparing the medicine for treating and/or preventing the liver metabolic diseases caused by the ionizing radiation.
Description
Technical Field
The invention relates to the field of biomedicine, in particular to application of selenium-rich probiotics in preparation of a medicine for treating and/or preventing radiation liver injury.
Background
Radiation therapy is a local treatment for tumors using radiation, and about 70% of cancer patients require radiation therapy in the course of treating cancer, and about 40% of cancers can be cured by radiation therapy. The role and position of radiotherapy in tumor treatment are increasingly prominent, and the radiotherapy has become one of the main means for treating malignant tumors. Although radiation therapy has made great progress, the normal tissue surrounding the tumor is also damaged by the treatment. Among them, the liver is one of radiation-sensitive organs and is extremely sensitive to radiation damage. Moreover, the liver is generally regarded as the most important organ of the human body and plays a vital role in immune activity, blood filtration and detoxification. It was found that ionizing radiation-induced changes in biochemical parameters revealed liver dysfunction in mice, indicating vulnerability of the liver to radiation exposure. Thus, in order to obtain better tumor control at higher doses of radiation, normal tissue should be protected from radiation damage. However, currently the only radioprotectant available for clinical use is amifostine. Amifostine is approved by the FDA for the treatment of mucositis and xerostomia in patients with radiotherapy for head and neck cancer, but causes severe side effects such as behavioral toxicity and nausea and vomiting. Therefore, the development of new radioprotective agents is essential.
Selenium (Se) is an essential element for humans and animals. It is a basic component of some antioxidant enzymes such as glutathione peroxidase (GSH-Px), thioredoxin reductase (TrxR) and selenoprotein P (SelP), and plays a key role in antioxidant defense systems. The intake of selenium as dietary supplement shows preventive effects such as resistance to gene mutation, anti-inflammation, etc. in various model organisms.
Probiotics are nonpathogenic microorganisms that have a positive impact on host health, and such microorganisms can potentially improve the intestinal microbiota and inhibit the attack of pathogenic bacteria on the human gut. Among them, bifidobacteria are good live microbial feed supplements, which are able to bind, absorb inorganic selenium and convert it into organic selenium. Under favourable conditions, bifidobacteria are able to convert elemental selenium into organic compounds, bringing health-related benefits to humans and animals. Additionally, probiotics are also considered as a possible additive therapy for the treatment of liver diseases caused by viral infections, alcoholism and metabolic disorders. Patent CN103599135B discloses a microecological solid preparation for treating alcoholic liver injury, which comprises bifidobacterium longum NQ-1501. Patent CN109486715A discloses a selenium-rich Bifidobacterium longum and its application in preparing medicine for improving diabetes and diabetic liver pathological changes.
The selenium compound can reduce abnormal rise of liver oxidation level of a mouse with liver injury induced by ionizing radiation, and no relevant research is carried out on whether probiotics and selenium-rich probiotics can relieve liver injury induced by ionizing radiation, so that the invention aims to explore the relieving effect of the selenium-rich bifidobacterium longum DD98 strain on X-ray radiation induced radiation liver injury.
Disclosure of Invention
Aiming at the defects, the invention provides the application of selenium-rich probiotics in the preparation of the medicine for treating and/or preventing the radiation liver injury. According to the invention, a 3Gy X-ray radiation induced radiation liver injury mouse model is utilized, and the selenium-rich probiotics are administered through long-term intragastric administration, so that the selenium-rich probiotics can relieve the reduction of the weight and the liver index of the X-ray radiation induced radiation liver injury mouse, the increase of the related serum index level and the injury of related visceral organs.
In order to achieve the above object, the technical solution of the present invention is as follows:
on one hand, the invention provides application of selenium-rich probiotics in preparation of a medicine for treating and/or preventing radiation liver injury.
Specifically, the application comprises the following steps:
(1) Relieving the weight and liver index reduction caused by radiation liver injury;
(2) Relieving the increase of the oxidative stress level of the liver caused by the radiation liver injury;
(3) Relieving the reduction of the content of the antioxidant enzyme in the liver caused by the radiation liver injury;
(4) Regulating the level of a liver inflammatory factor caused by radiation liver injury;
(5) Relieving pathological damage of liver caused by radiation liver injury.
Specifically, the selenium-rich probiotics is a selenium-rich bifidobacterium longum DD98 strain, and the preservation number of the bifidobacterium longum DD98 strain is CGMCC No.16573.
More specifically, the preparation method of the selenium-enriched bifidobacterium longum DD98 strain comprises the steps of inoculating the bifidobacterium longum DD98 strain into an RCM modified culture medium, carrying out anaerobic culture at 37 ℃ for 12 hours, adding sodium selenite (with the concentration of 18.5 mu g/mL) into the culture medium, continuing to culture for 24 hours, keeping the pH value constant at 6.8, and fermenting under a high-selenium environment to prepare the selenium-enriched bifidobacterium longum DD98. Through high-throughput screening and selenium-enriched culture, the strain with good tolerance and transformation capability to selenium is obtained.
Further specifically, the RCM modified medium: 1% of beef extract, 0.5% of peptone, 0.3% of yeast powder, 0.6% of glucose, 0.5% of sodium chloride, 0.3% of anhydrous sodium acetate, 0.05% of L-cysteine hydrochloride and 1.5-1.8% of agar.
More specifically, the dosage (counted by viable count) of the selenium-rich bifidobacterium longum DD98 strain is 1-10 multiplied by 10 8 CFU/kg body weight, preferably 2.7-5.4X 10 8 CFU/kg body weight, more preferably 5.4X 10 8 CFU/kg body weight.
More specifically, the dosage (by selenium content) of the selenium-enriched bifidobacterium longum DD98 strain is 0.05-0.3mg Se/kg body weight, preferably 0.1-0.2mg Se/kg body weight, and more preferably 0.2mg Se/kg body weight.
On the other hand, the invention provides application of selenium-rich probiotic powder in preparation of a medicine for treating and/or preventing radiation liver injury, wherein the selenium-rich probiotic powder is selenium-rich bifidobacterium longum DD98 strain powder, and the preservation number of the bifidobacterium longum DD98 strain is CGMCC No.16573.
Specifically, the preparation method of the selenium-rich bifidobacterium longum DD98 strain powder comprises the following steps: inoculating the Bifidobacterium longum DD98 strain in RCM modified culture medium, anaerobically culturing at 37 deg.C for 12 hr, adding sodium selenite (concentration of 18.5 μ g/mL) into the culture medium, continuously culturing for 24 hr with constant pH of 6.8, and fermenting under high selenium environment to obtain selenium-rich Bifidobacterium longum DD98. Centrifuging selenium-enriched bifidobacterium longum DD98 strain Se-DD98, collecting thalli, mixing the thalli with a protective agent according to a ratio of 1.
Further specifically, the protective agent is 16% of skimmed milk powder, 31% of trehalose, 3% of sodium ascorbate and 50% of water.
More specifically, the using dosage of the selenium-enriched bifidobacterium longum DD98 strain powder is 0.1-0.5g of powder/kg of body weight, preferably 0.2-0.4g of powder/kg of body weight, and more preferably 0.4g of powder/kg of body weight.
More specifically, the content of the selenium-rich bifidobacterium longum DD98 strain powder is 1-10 multiplied by 10 9 CFU/g bacterial powder, preferably 1.35X 10 9 CFU/g bacterial powder.
More specifically, the selenium content of the selenium-enriched bifidobacterium longum DD98 strain powder is 0.4-0.6mg Se/g strain powder, and preferably 0.5mg Se/g strain powder.
In certain embodiments, the study methods of the present invention are as follows:
the mice are divided into a normal control group, a radiation control group, a bifidobacterium longum DD98 (DD 98) control group, a selenium-enriched bifidobacterium longum DD98 (Se-DD 98) low-dose group and a Se-DD98 high-dose group. The normal control group and the radiation control group are filled with stomach sterile normal saline, and DD98 bacteria powder without selenium added during stomach filling of DD98 group is dissolved in normal saline (viable count is 5.4 × 10) 8 CFU/kg), se-DD98 low dose group gastric lavage Se-DD98 bacterial powder dissolved in normal saline (viable count is 2.7 multiplied by 10) 8 CFU/kg), se-DD98 high dose group gastric lavage Se-DD98 bacterial powder dissolved in normal saline (viable count 5.4X 10) 8 CFU/kg). The gavage is continued for 28 days, and the X-ray irradiation is performed on 29 days(except for a normal control group), the dose rate is 1Gy/min, the irradiation time is 3min, the skin source irradiation distance is 100cm, and the dose is 3.0Gy, a 3Gy X-ray radiation induced radiation liver injury mouse model is established, 2 nd rhizoma gastrodiae is used for killing each group of mice after irradiation, blood is taken from eye sockets, 3000rpm and 10min centrifugation are carried out, and serum is reserved for later use. The liver was rapidly stripped and kept for future use.
Compared with the prior art, the invention has the advantages that:
1. the invention adopts an animal experiment model to establish a radiation liver injury mouse model, and researches the influence of selenium-rich probiotics on radiation liver injury caused by X-ray radiation, including weight and liver index change, liver oxidation and oxidation resistance level change and liver inflammation level.
2. The invention provides application of selenium-rich probiotics in adjusting the weight and liver index of a mouse with radioactive liver injury induced by X-ray radiation, the liver oxidation and antioxidation level and the liver inflammation level, and provides a new idea for preparing a medicament for treating and/or preventing liver metabolic diseases caused by ionizing radiation.
Deposit description
And (3) classification and naming: bifidobacterium longum
Latin name: bifidobacterium longum
According to the biological material: DD98
The preservation organization: china general microbiological culture Collection center
The preservation organization is abbreviated as: CGMCC (China general microbiological culture Collection center)
And (4) storage address: xilu No.1 Hospital No. 3, the institute of microbiology, china academy of sciences, beijing, chaoyang
The preservation date is as follows: 10 and 11 months in 2018
Registration number of the preservation center: CGMCC No.16573
Drawings
FIG. 1 is a graph showing the results of the change in fasting body weight of mice.
FIG. 2 is a graph showing the results of mouse liver index changes.
FIG. 3 is a graph showing the results of the serum ALT changes in mice.
FIG. 4 is a graph showing the results of the change in serum AST in mice.
FIG. 5 is a graph showing the results of changes in MDA content in mouse liver.
FIG. 6 is a graph showing the results of the change of LDH content in mouse liver.
FIG. 7 is a graph showing the results of CAT changes in mouse liver.
FIG. 8 is a graph showing the results of mouse liver SOD changes.
FIG. 9 is a graph showing the results of changes in mouse liver GSH-Px.
FIG. 10 is a graph showing the results of changes in IL-1. Beta. Content in mice.
FIG. 11 is a graph showing the results of changes in IL-6 content in mice.
FIG. 12 is a graph showing the results of changes in mouse TNF-. Alpha.content.
FIG. 13 is a graph showing the results of changes in IL-10 content in mice.
FIG. 14 is a graph showing the results of pathological morphological changes in mouse liver.
Detailed Description
The present invention will be further illustrated in detail with reference to the following specific examples, which are not intended to limit the present invention but are merely illustrative thereof. The experimental methods used in the following examples are not specifically described, and the materials, reagents and the like used in the following examples are generally commercially available under the usual conditions without specific descriptions.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
In certain embodiments, the medicament of the invention is used for alleviating X-ray induced reduction in body weight and liver index in mice with radiation liver injury.
In certain embodiments, the medicament of the invention is used for relieving the increase of serum liver function indexes of mice with X-ray induced radiation liver injury.
In certain embodiments, the medicament of the invention is used for reducing the level of oxidative stress in the liver of an X-ray induced radiation liver injury mouse.
In certain embodiments, the medicament of the invention is used for improving the activity of liver antioxidase in mice with X-ray induced radioactive liver injury.
In certain embodiments, the medicament of the invention is used for reducing the increase of pro-inflammatory cytokines in the liver of a mouse with X-ray induced radiation liver injury.
In certain embodiments, the medicament of the invention is used for increasing the level of anti-inflammatory cytokines in liver of mice with X-ray induced radiation liver injury.
In certain embodiments, the medicament of the invention is used for alleviating liver tissue damage in an X-ray induced radiation liver damage mouse.
In the examples of the present invention, the experimental data are shown as mean. + -. Standard deviation
Showing that the difference between groups was analyzed by one-way ANOVA, and a-d indicates that groups with different letters in the same index have significant difference between groups (p)<0.05 Identical letter groups indicate no significant difference between groups.
In certain embodiments, the medicament of the present invention further comprises any pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier that is pharmacologically and/or physiologically compatible with the subject and active ingredient, and is well known in the art (see, e.g., remington's Pharmaceutical sciences. Edited by Gennaro AR,19th ed. Pennsylvania: pH adjusting agents, surfactants, adjuvants, ionic strength enhancers, diluents, agents to maintain osmotic pressure, agents to delay absorption, preservatives. For example, pH adjusting agents include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. Agents that maintain osmotic pressure include, but are not limited to, sugars, naCl, and the like. Agents that delay absorption include, but are not limited to, monostearate salts and gelatin. Diluents include, but are not limited to, water, aqueous buffers (e.g., buffered saline), alcohols and polyols (e.g., glycerol), and the like. Preservatives include, but are not limited to, various antibacterial and antifungal agents, for example, thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, and the like. Stabilizers have the meaning generally understood by those skilled in the art to stabilize the desired activity of the active ingredient in a medicament, and include, but are not limited to, sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin, or casein) or degradation products thereof (such as milk albumin hydrolysate), and the like.
The term "subject" refers to a mammal, e.g., a primate mammal, a non-human primate mammal, or a human. In certain embodiments, the subject (e.g., a mouse) has, or is at risk of having, 3Gy X-ray radiation induced radiation liver injury.
The term "effective amount" refers to an amount sufficient to obtain, or at least partially obtain, the desired effect. For example, a disease-preventing effective amount refers to an amount sufficient to prevent, arrest, or delay the onset of disease; a therapeutically effective amount for a disease is an amount sufficient to cure or at least partially arrest the disease and its complications in a patient already suffering from the disease. It is well within the ability of those skilled in the art to determine such effective amounts. For example, an amount effective for therapeutic use will depend on the severity of the disease to be treated, the general state of the patient's own immune system, the general condition of the patient, e.g., age, weight and sex, the mode of administration of the drug, and other treatments administered concurrently, and the like.
The pharmaceutical compositions may be in any suitable form, depending on the desired method of administering them to a patient, and the combination compositions of the present invention may be administered to a patient by a variety of routes, such as orally, transdermally, subcutaneously, intranasally, intravenously, intramuscularly, intraocularly, topically, intrathecally, and intracerebroventricularly. The route of administration most suitable in any given case will depend on the particular pharmaceutical composition, the individual and the nature and severity of the disease and the physical condition of the individual.
TABLE 1 English abbreviation list
Example 1 preparation of Se-DD98 bacterial powder
RCM modified medium: 1% of beef extract, 0.5% of peptone, 0.3% of yeast powder, 0.6% of glucose, 0.5% of sodium chloride, 0.3% of anhydrous sodium acetate, 0.05% of L-cysteine hydrochloride and 1.5-1.8% of agar.
And (3) a protective agent: 16% of skimmed milk powder, 31% of trehalose, 3% of sodium ascorbate and 50% of water.
The preparation method of the fungus powder comprises the following steps: inoculating a bifidobacterium longum DD98 strain (the preservation number of the bifidobacterium longum DD98 strain is CGMCC No. 16573) into an RCM modified culture medium, carrying out anaerobic culture at 37 ℃ for 12h, adding sodium selenite (the concentration is 18.5 mu g/mL) into the culture medium, continuing to culture for 24h, keeping the pH value constant at 6.8, and fermenting under a high-selenium environment to prepare the selenium-enriched DD98 fermentation liquor. Collecting Se-DD98 bacterial liquid, centrifuging at 14000r/min for 10min at high speed, discarding supernatant, and washing the centrifuged thallus with sterile normal saline (0.9%) for three times to obtain concentrated Se-DD98. Mixing the Se-DD98 concentrated bacterial liquid with a protective agent according to a ratio of 1.
The method for detecting the selenium content in Se-DD98 bacterial powder refers to the national standard GB5009.93-2010 determination of selenium in food.
And (3) determining the number of live bacteria in Se-DD98 bacteria powder: taking a proper amount of bacterial powder into a 1.5mL centrifuge tube, adding 1.0mL of sterile normal saline into the centrifuge tube, carrying out vortex oscillation until the bacterial powder is completely dissolved, adopting a gradient dilution method to reach a proper dilution degree, carrying out plate coating, carrying out anaerobic culture at 37 ℃ for 48h, and taking out the bacterial powder for viable count when bacterial colonies are clearly visible and the size of the bacterial colonies is proper. Viable count (CFU/mL) = (sum of colonies on 3 plates)/3 × 10 final dilution.
Example 2 radiation liver injury mouse model and dosing assay
The mice were randomly divided into 5 groups,each group comprises 6 individuals, including normal control group, radiation control group, bifidobacterium longum DD98 (DD 98) control group, selenium-rich Bifidobacterium longum DD98 (Se-DD 98) low dose group, and Se-DD98 high dose group. The normal control group and the radiation control group are filled with stomach sterile normal saline, DD98 bacteria powder without selenium in DD98 group is dissolved in normal saline (viable count is 5.4 × 10) 8 CFU/kg), se-DD98 low dose group lavage Se concentration of 0.1mg/kg Se-DD98 bacterial powder dissolved in normal saline (viable count of 2.7 multiplied by 10) 8 CFU/kg), se-DD98 high dose group lavage Se concentration of 0.2mg/kg Se-DD98 bacterial powder dissolved in normal saline (viable count of 5.4 multiplied by 10) 8 CFU/kg). The gavage volume was 0.1mL/10g,1 times/day. Continuously performing intragastric administration for 28 days, performing X-ray irradiation (except for a normal control group) on the 29 th day at the dose rate of 1Gy/min for 3min, at the skin source irradiation distance of 100cm and at the dose of 3.0Gy, establishing a 3Gy X-ray radiation induced radiation liver injury mouse model, killing mice of each group after the irradiation by intoxicating the 2 nd rhizoma gastrodiae, taking blood from an orbit, centrifuging at 3000rpm and 10min, and reserving serum for later use. The liver was rapidly stripped and kept for future use.
Table 2 experimental grouping and dosing
Example 3 mouse body weight Change
After fasting the mice for 12 hours, the fasting body weight of the mice was measured. FIG. 1 shows the results of the change in fasting body weight of mice.
As can be seen from fig. 1, there was no significant difference in initial body weight of each group of mice, and the initial body weight tended to increase slowly. After 28 days of intragastric administration, there was no significant change in body weight between each administration group and the normal control group, indicating that Se-DD98 and DD98 were not acutely toxic to mice at the selected doses. On day 2 after 3Gy X-ray irradiation, the mice in the irradiated control group exhibited a significant decrease in body weight (24.4 g) as compared to the normal control group, indicating that the dose of 3Gy X-ray irradiation was sufficient to cause a rapid and significant decrease in body weight in the mice. It is worth noting that the body weight of the DD98 strain control group is increased to a certain extent compared with the radiation control group, but the effect is slight and has no significant difference, which indicates that the DD98 strain powder can not significantly relieve the abnormal weight reduction of the mice caused by the X-ray radiation. The weight (26.94 g) of the mice in the Se-DD98 high-dose group is obviously higher than that of the mice in the radiation control group, and has no obvious difference compared with the normal control group, which shows that the combination of Se and DD98 bacterial powder enhances the effect of DD98 bacterial powder on reducing abnormal weight reduction of the mice induced by X-ray radiation. The result proves that the abnormal reduction of the body weight of the mice caused by X-ray radiation can be relieved dose-dependently by preventively administering the Se-DD98 bacterial powder, and the effect is better than that of the DD98 bacterial powder.
Example 4 mouse liver index Change
After the mice were sacrificed, the livers were washed in cold physiological saline, excess water was blotted, the liver weights were weighed, and the liver index was calculated. FIG. 2 shows the change of mouse liver index.
As can be seen from FIG. 2, the liver index of the mice in the irradiated control group was significantly reduced by 14.7% compared to the normal control group on day 2 after 3Gy X-ray irradiation, indicating that the dose of 3Gy X-ray irradiation was sufficient to cause liver injury in the mice. It is worth noting that compared with the radiation control group, the liver index of the DD98 simple control group is increased to a certain extent, but the effect is slight and has no obvious difference, which indicates that the DD98 simple bacterial powder can not obviously relieve the abnormal reduction of the liver index of the mouse caused by the X-ray radiation. The liver index of the mice in the Se-DD98 high-dose group is obviously higher than that of the mice in the radiation control group and the Se-DD98 low-dose group, and has no obvious difference compared with the normal control group, which shows that the combination of the Se and the DD98 bacterial powder strengthens the effect of the DD98 bacterial powder on reducing the X-ray radiation to cause the abnormal reduction of the liver index of the mice. The result proves that the Se-DD98 bacterial powder can be used for preventing and feeding the Se-DD98 bacterial powder to relieve the abnormal reduction of the mouse liver index induced by X-ray radiation in a dose-dependent manner, and the effect is better than that of the DD98 bacterial powder.
Example 5 mouse serum transaminase changes
On the 2 nd day after irradiation, the mice in each group are fasted for 12h, blood is taken from the orbit, 3000r/min is carried out, the centrifugation is carried out for 10min, and the supernatant is taken to obtain serum, and the serum is analyzed and detected by an enzyme labeling instrument according to the operation of ALT and AST kits. FIG. 3 shows the change in serum ALT of mice, and FIG. 4 shows the change in serum AST of mice.
As can be seen from FIG. 3, after 3Gy X-ray irradiation, the serum ALT (24.01U/L) level of the mice in the irradiation control group is significantly increased by 76.5%, compared with the normal control group, which indicates that the 3Gy X-ray dose is enough to cause the liver injury of the mice. In this study, ionizing radiation significantly altered serum biochemical markers of the liver, indicating that the liver was compromised. Notably, compared with the irradiation control group, the serum ALT (15.11U/L) of the DD98 mice is remarkably reduced, which indicates that the DD98 bacteria powder has the effect of relieving the liver injury of the mice caused by X-ray radiation. Compared with the Se-DD98 low dose group and the DD98 control group, the Se-DD98 high dose group further reduces the serum ALT content level and recovers to the normal level, which shows that the Se-DD98 bacterial powder can more remarkably relieve the abnormal elevation of the mouse serum ALT caused by X-ray radiation compared with the DD98 bacterial powder. The result proves that the Se-DD98 bacterial powder can relieve ALT abnormal rise of mice with radiation liver injury induced by X-ray radiation, and the effect is better than that of the DD98 bacterial powder group.
As can be seen from FIG. 4, after 3Gy X-ray irradiation, the level of AST (27.94U/L) in the serum of the mice in the irradiation control group is significantly increased by 9.8% compared with the normal control group, which again indicates that the 3Gy X-ray dose is enough to cause the liver injury of the mice. Notably, compared with the radiation control group, the serum AST (23.23U/L) of the DD98 group mice is obviously reduced, which indicates that the DD98 bacteria powder has the effect of relieving the liver injury of the mice caused by X-ray radiation. Compared with the Se-DD98 low dose group, the Se-DD98 high dose group further reduces the serum AST content level and returns to the normal level, which shows that the Se-DD98 bacterial powder can release the abnormal increase of the serum AST of the mice caused by X-ray radiation in a dose-dependent manner. The result proves that the Se-DD98 and DD98 bacteria powder which are given preventively can relieve the abnormal increase of the AST in the serum of the mice with the radiation liver injury induced by the X-ray radiation.
The existing research shows that the activity of ALT and AST liver function in serum is increased, which indicates that the permeability of cells is enhanced or membranes are broken, so the ALT and AST level in serum is often used as the biochemical index of clinical liver injury. The analysis results show that the Se-DD98 bacteria powder can obviously inhibit the abnormal increase of serum ALT and AST of the mice with the radiation liver injury induced by X-ray radiation in a dose-dependent manner and relieve the liver injury.
Example 6 Change in indicators of oxidative stress in mouse liver
Weighing mouse liver, adding physiological saline to homogenate at 3000r/min, centrifuging for 10min, taking supernatant, and determining MDA and LDH content in liver according to the operation of kit specification. Fig. 5 is the change in MDA content in the liver and fig. 6 is the change in LDH content in the liver.
As can be seen from FIG. 5, compared with the normal control group, MDA (2.03 nmol/mg prot) in the liver of the radiation control group is significantly increased by 32.7%, indicating that the liver lipid peroxidation is caused after 3Gy X-ray irradiation, which causes radiation liver injury. It is worth noting that, compared with the radiation control group, the MDA content in the liver of the DD98 bacteria powder group is reduced to a certain extent, but no significant difference exists, which indicates that the DD98 bacteria powder has the effect of reducing the MDA content in the liver caused by the radiation liver injury to a certain extent, but the effect is slight and no significant difference exists. The MDA content in the mouse liver of the Se-DD98 high-dose group is lower than that of the single DD98 bacterial powder group and that of the Se-DD98 low-dose group, and the difference with the normal control group is not obvious, so that the combination of the Se and the DD98 bacterial powder strengthens the effect of the DD98 bacterial powder on reducing abnormal increase of the MDA content in the mouse liver caused by X-ray radiation. The result proves that the dose-dependent reduction of the liver MDA level of a mouse with the radioactive liver injury can be realized by the preventive administration of the Se-DD98 bacterium powder, and the effect is better than that of the DD98 bacterium powder.
As can be seen from FIG. 6, compared with the normal control group, LDH (6.69 nmol/mg prot) in the liver of the radiation control group is significantly increased by 25.4%, and the result shows that the irradiation of 3Gy X-ray causes hepatotoxicity of mice and causes radiation liver injury. It is worth noting that compared with the radiation control group, the LDH content in the liver of the DD98 bacteria powder group is reduced to a certain extent, but no significant difference exists, which indicates that the DD98 bacteria powder has the function of reducing the liver content increase caused by the radiation liver injury to a certain extent, but the effect is slight. The LDH content of the liver of the mice in the Se-DD98 high-dose group is obviously lower than that of the mice in the radiation control group and the DD98 bacteria powder group, and the synergistic effect of the combination of the Se and the DD98 bacteria powder strengthens the effect of the DD98 bacteria powder on reducing abnormal increase of the LDH content of the liver of the mice caused by X-ray induced radiation liver injury. Similar results were observed in the low dose group of Se-DD98 but with no significant differences. The result proves that the Se-DD98 bacteria powder for preventive administration can reduce the level of liver LDH of mice with radiation liver injury in a dose-dependent manner, and the effect is superior to that of the DD98 bacteria powder.
Studies have shown that Malondialdehyde (MDA) content is expressed as a level of lipid peroxidation and is indicative of cell or tissue damage level, LDH content is indicative of cytotoxicity and is indicative of cell damage. In conclusion, the increase of MDA and LDH in the liver of the mouse caused by the radioactive liver injury can be reduced by the preventive administration of the Se-DD98 strain powder, the liver lipid peroxidation caused by X-ray radiation is further relieved, and the Se-DD98 strain powder has a certain relieving effect on the radioactive liver injury.
Example 7 changes in the mouse liver oxidative defense indicators
Weighing mouse liver, adding physiological saline to homogenate at 3000r/min, centrifuging for 10min, taking supernatant, and determining CAT, SOD and GSH-Px content in liver according to the operation of kit instruction. Fig. 7 shows the change in liver CAT, fig. 8 shows the change in liver SOD, and fig. 9 shows the change in liver GSH-Px.
As can be seen from FIG. 7, compared with the normal control group, the CAT (16.2U/mg Prot) activity in the liver of the radiation control group is significantly reduced, which indicates that the radiation liver injury induced by 3Gy X-ray radiation can cause the reduction of CAT content in the liver of the mouse. It is worth noting that compared with the mice in the radiation control group, the liver CAT activity of the mice in the DD98 bacterium powder group is obviously improved, which indicates that the DD98 bacterium powder has the effect of relieving the abnormal reduction of the liver CAT activity caused by the radiation liver injury. The CAT content in the liver of the mice in the Se-DD98 high-dose and low-dose groups is slightly higher than that in the DD98 group, which shows that the combination of Se and DD98 enhances the effect of DD98 bacterial powder on reducing abnormal reduction of the CAT content in the liver of the mice caused by radiation liver injury. The result proves that the prophylactic administration of the Se-DD98 bacterial powder can improve the level of CAT in the liver of a mouse with radioactive liver injury.
As can be seen from FIG. 8, compared with the normal control group, the activity of SOD (34.32U/mg Prot) in the liver of the radiation control group is significantly reduced, which indicates that the radiation liver injury induced by 3Gy X-ray radiation can cause the reduction of the SOD content in the liver of the mouse, leading to the failure of the antioxidant defense mechanism and further leading to tissue damage. It is worth noting that compared with the radiation control group, the liver SOD content of the mice in the DD98 bacteria powder control group is not obviously improved, which indicates that the reduction of the liver SOD content of the mice caused by the radiation liver injury can not be relieved by using the DD98 bacteria powder alone. The liver SOD content of the Se-DD98 high/low dose mice is higher than that of the radiation control group and the DD98 bacteria powder control group, which shows that the synergistic effect of the combination of Se and DD98 bacteria powder is higher than that of the DD98 bacteria powder used alone. The result proves that the Se-DD98 bacterial powder can relieve the reduction of the liver antioxidant enzyme SOD level of a mouse with radioactive liver injury by preventively administering the Se-DD98 bacterial powder, and the effect is better than that of the DD98 bacterial powder.
As can be seen from FIG. 9, the GSH-Px (1658.22U/mg Prot) activity in the liver of the radiation control group is significantly reduced compared with that of the normal control group, which indicates that the radioactive liver injury induced by 3Gy X-ray radiation can cause the GSH-Px content in the liver of the mouse to be reduced, so that the antioxidant defense mechanism is disabled, and further, the tissue injury is caused. Notably, compared with a radiation control group, the content of the liver GSH-Px of the mice in the DD98 bacterium powder control group is obviously increased, which indicates that the DD98 bacterium powder alone has the effect of relieving the reduction of the content of the liver GSH-Px of the mice caused by the radiation liver injury. The liver GSH-Px content of the mice in the Se-DD98 high dose group and the Se-DD98 low dose group is higher than that of the mice in the radiation control group. The result proves that the Se-DD98 bacterial powder can be used for dose-dependently relieving the reduction of the level of the liver antioxidant enzyme GSH-Px of the mice with the radiation liver injury.
In conclusion, the Se-DD98 bacteria powder can relieve CAT, SOD and GSH-Px activity reduction of mouse liver caused by radiation liver injury through preventive administration, so that abnormal increase of MDA and LDH content of mouse liver caused by radiation liver injury is reduced, further damage of an antioxidant defense system caused by radiation liver injury is relieved, in-vivo antioxidant level is improved, tissue injury is improved, and damage of ionizing radiation to the liver oxidation defense system is fundamentally relieved.
Example 8 changes in mouse hepatic IL-1 β, IL-6, TNF- α and IL-10 levels
On the 2 nd day after irradiation, mice in each group are fasted for 12h, livers are taken out, total mRNA is extracted, reverse transcription is carried out, and relative expression amounts of IL-1 beta, IL-6, TNF-alpha and IL-10 are determined by a qPCR method. FIG. 10 shows the change in IL-1. Beta. Content, FIG. 11 shows the change in IL-6 content, FIG. 12 shows the change in TNF-. Alpha. Content, and FIG. 13 shows the change in IL-10 content.
As can be seen from FIG. 10, compared with the normal control group, the liver interleukin IL-1 beta content of the mice in the radiation control group, the DD98 control group and the Se-DD98 low-dose group is obviously increased, which indicates that the X-ray radiation can cause the increase of the liver proinflammatory factor IL-1 beta content of the mice. It is noted that compared with the radiation control group, the IL-1 beta in the liver of the DD98 control group is reduced to a certain extent, which indicates that the DD98 bacterial powder alone relieves the increase of the proinflammatory factor IL-1 beta content of the mouse liver caused by the ionizing radiation, but the effect is slight and has no significant difference. IL-1 beta in livers of the Se-DD98 high-dose group and the Se-DD98 low-dose group is obviously lower than that of a radiation control group and a DD98 control group, which shows that the Se-DD98 bacterial powder can more obviously relieve abnormal increase of proinflammatory cytokines IL-1 beta in livers of mice caused by ionizing radiation compared with the DD98 bacterial powder. The result proves that the increase of the content of the IL-1 beta in the liver of a mouse with the radioactive liver injury can be reduced by preventively administering the Se-DD98 bacteria powder, and the effect is better than that of the DD98 bacteria powder.
As can be seen from FIG. 11, compared with the normal control group, the liver interleukin IL-6 content of the mice in the irradiation control group is obviously increased, which indicates that the X-ray irradiation can cause the liver proinflammatory factor IL-6 content of the mice to be increased. It is worth noting that compared with the radiation control group, the IL-6 in the liver of the DD98 control group is reduced to a certain degree, which shows that the DD98 bacterial powder alone can relieve the increase of the proinflammatory factor IL-6 content in the liver of the mouse caused by the ionizing radiation, but the effect is not obvious. IL-6 in livers of the Se-DD98 high-dose group and the Se-DD98 low-dose group is obviously lower than that of a radiation control group, which shows that the Se-DD98 bacterial powder obviously relieves abnormal increase of proinflammatory cytokines IL-6 in the livers of mice caused by ionizing radiation. The result proves that the Se-DD98 bacterial powder for preventive administration can reduce the increase of the content of the IL-6 in the liver of a mouse with the radiation liver injury, and the effect is better than that of the DD98 bacterial powder.
As can be seen from FIG. 12, the content of TNF- α, a liver inflammatory factor, was significantly increased in all the other groups of mice as compared to the normal control group, indicating that X-ray radiation caused the increase of TNF- α in the liver of mice. It is worth noting that compared with a radiation control group, the content of the liver TNF-a in the DD98 control group is obviously reduced, and the DD98 bacterial powder has the effect of reducing abnormal rising of the content of the liver TNF-a of the mouse caused by radiation liver injury. The content of TNF-alpha in the liver of the mouse in the Se-DD98 high-dose group is lower than that of the mouse in the radiation control group, the DD98 control group and the Se-DD98 low-dose group, which shows that the combination of Se and DD98 strengthens the effect of DD98 bacteria powder on reducing abnormal increase of the content of TNF-alpha in the liver of the mouse caused by radiation liver injury. The result proves that the increase of the content of the TNF-alpha in the liver of a mouse with the radioactive liver injury can be reduced by preventively administering the Se-DD98 bacteria powder, and the effect is better than that of the DD98 bacteria powder.
As can be seen from FIG. 13, the IL-10 content in the liver of the mice in the radiation control group, the DD98 control group and the Se-DD98 low dose group was uniformly increased in a definite degree, but there was no significant difference, indicating that the ionizing radiation of the X-ray of 3Gy did not cause the compensatory increase of the anti-inflammatory cytokine IL-10 in the liver of the mice. It is worth noting that the IL-10 content in the liver of the mice in the Se-DD98 high-dose group is obviously higher than that in the normal control group, the radiation control group and the DD98 control group, and the Se-DD98 bacterial powder can improve the content of the anti-inflammatory cytokine IL-10 in the liver of the mice compared with the DD98 bacterial powder. The result proves that the content of the IL-10 in the liver of a mouse with the radioactive liver injury can be increased by preventively administering the Se-DD98 bacterium powder, and the effect is better than that of the DD98 bacterium powder.
In conclusion, the Se-DD98 bacterial powder can reduce abnormal increase of mouse liver proinflammatory factors caused by radiation liver injury and increase the content of mouse liver anti-inflammatory factors, thereby further relieving the liver injury caused by ionizing radiation.
Example 9H & E pathological morphometric changes in mouse liver
On day 2 after irradiation, the mice in each group were fasted for 12h, and the livers were immediately soaked in tissue fixative and stored for future use. The tissue is dehydrated in gradient, soaked in wax and embedded. A cross section of 5-7 μm thickness was taken, stained with hematoxylin and eosin (H & E), and histological changes were observed under an optical microscope. The results are shown in FIG. 14.
As can be seen from FIG. 14, the liver cells of the mice in the normal control group were densely arranged and normal in morphology. The radiation control group had dilated hyperemia of hepatic Central Vein (CV), ruptured endothelial layer, and obvious vascular channels emanating from central vein; significant expansion of the peripheral liver is seen; bile duct cell and fibrocyte hyperplasia can be seen around a small amount of hepatic lobules and a manifold area; the cytoplasmosis is slight, the liver cell cytoplasm is dissolved and disappeared, and the karyocyte is shrunk and shrunk a little or disappears, which indicates that the ionizing radiation can cause pathological damage to the liver tissue of the mouse. It is noted that the pathological damage of the liver tissue of the mice in the DD98 control group is reduced, but the central vein still has obvious dilatation hyperemia, which indicates that the DD98 bacterial powder has the function of relieving the pathological damage of the liver tissue of the mice caused by ionizing radiation. The liver cells of the mice in the Se-DD98 high-dose group and the Se-DD98 low-dose group are arranged closely, the central veins have no obvious dilatation congestion, the infiltration of inflammatory cells is reduced, and the normal liver tissue structure is displayed, which shows that the potential of the Se-DD98 in protecting tissues from the X-ray induced liver tissue structure damage is given preventively, thus suggesting the potential of the Se-DD98 in radiation protection, and the effect is better than that of the DD98 bacterial powder.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that various changes and modifications can be made by those skilled in the art without departing from the spirit of the invention, and these changes and modifications are all within the scope of the invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (5)
1. The application of selenium-rich probiotics in preparation of medicines for treating and/or preventing radiation liver injury is characterized in that the selenium-rich probiotics are selenium-rich bifidobacterium longum DD98 strains, and the preservation number of the bifidobacterium longum DD98 strains is CGMCC No. 16573;
the dosage of the selenium-rich Bifidobacterium longum DD98 strain is 5.4 × 10 in terms of viable count 8 CFU/kg body weight; the dosage of the selenium-rich bifidobacterium longum DD98 strain is 0.2mgSe/kg body weight in terms of selenium content;
the preparation method of the selenium-enriched bifidobacterium longum DD98 strain comprises the following steps: inoculating the Bifidobacterium longum DD98 strain into an RCM modified culture medium, carrying out anaerobic culture at 37 ℃ for 12h, adding 18.5 mu g/mL sodium selenite into the culture medium, continuing to culture for 24h with a constant pH value of 6.8, and fermenting under a high-selenium environment to prepare the selenium-enriched Bifidobacterium longum DD98;
the RCM modified culture medium comprises: 1% of beef extract, 0.5% of peptone, 0.3% of yeast powder, 0.6% of glucose, 0.5% of sodium chloride, 0.3% of anhydrous sodium acetate, 0.05% of L-cysteine hydrochloride and 1.5-1.8% of agar.
2. The application of claim 1, wherein the application comprises:
(1) Relieving the weight and liver index reduction caused by radiation liver injury;
(2) Relieving the increase of the oxidative stress level of the liver caused by the radiation liver injury;
(3) Relieving the reduction of the content of the antioxidant enzyme in the liver caused by the radiation liver injury;
(4) Modulating the level of a liver inflammatory factor caused by radiation liver injury;
(5) Relieving pathological damage of liver caused by radiation liver injury.
3. The application of selenium-rich probiotic bacteria powder in the preparation of the medicine for treating and/or preventing the radiation liver injury is characterized in that the selenium-rich probiotic bacteria powder is selenium-rich bifidobacterium longum DD98 strain powder, and the preservation number of the bifidobacterium longum DD98 strain is CGMCC No. 16573;
the preparation method of the selenium-rich bifidobacterium longum DD98 strain powder comprises the following steps:
inoculating the Bifidobacterium longum DD98 strain into an RCM modified culture medium, carrying out anaerobic culture at 37 ℃ for 12h, adding 18.5 mu g/mL sodium selenite into the culture medium, continuing to culture for 24h with a constant pH value of 6.8, fermenting under a high-selenium environment to prepare the selenium-enriched Bifidobacterium longum DD98, centrifuging the selenium-enriched Bifidobacterium longum DD98 strain Se-DD98, collecting the strain, mixing the strain with a protective agent according to a ratio of 1;
the RCM modified culture medium comprises: 1% of beef extract, 0.5% of peptone, 0.3% of yeast powder, 0.6% of glucose, 0.5% of sodium chloride, 0.3% of anhydrous sodium acetate, 0.05% of L-cysteine hydrochloride and 1.5-1.8% of agar; the protective agent comprises 16% of skimmed milk powder, 31% of trehalose, 3% of sodium ascorbate and 50% of water.
4. The use according to claim 3, wherein the selenium-enriched Bifidobacterium longum DD98 strain powder is used in an amount of 0.1-0.5g powder/kg body weight; the content of the selenium-rich Bifidobacterium longum DD98 strain powder is 1-10 × 10 9 CFU/g bacterial powder; the selenium content of the selenium-rich bifidobacterium longum DD98 strain powder is 0.4-0.6mgSe/g strain powder.
5. The use according to claim 4, wherein the selenium-enriched Bifidobacterium longum DD98 strain powder is used in an amount of 0.2-0.4g powder/kg body weight; the content of the selenium-rich Bifidobacterium longum DD98 strain powder is 1.35 × 10 9 CFU/g bacterial powder; the selenium content of the selenium-rich bifidobacterium longum DD98 strain powder is 0.5mg Se/g strain powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110219055.1A CN112807328B (en) | 2021-02-26 | 2021-02-26 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110219055.1A CN112807328B (en) | 2021-02-26 | 2021-02-26 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112807328A CN112807328A (en) | 2021-05-18 |
| CN112807328B true CN112807328B (en) | 2023-04-11 |
Family
ID=75864151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110219055.1A Active CN112807328B (en) | 2021-02-26 | 2021-02-26 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112807328B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599135A (en) * | 2013-10-30 | 2014-02-26 | 内蒙古双奇药业股份有限公司 | Solid-phase microecology preparation used for treating alcoholic liver injuries, and preparation method thereof |
| JP2018118915A (en) * | 2017-01-24 | 2018-08-02 | 雪印メグミルク株式会社 | Non-alcoholic liver injury inhibitor |
| CN109486715A (en) * | 2018-12-07 | 2019-03-19 | 江苏靶标生物医药研究所有限公司 | A kind of selenium-rich bifidobacterium longum and its preparation method and application |
| CN109929773A (en) * | 2019-01-10 | 2019-06-25 | 江苏德禧生物科技有限公司 | One plant of Bifidobacterium that can be used for selenium-rich culturing and its activated protein and application |
| CN111996153A (en) * | 2020-09-18 | 2020-11-27 | 南京益瑞兰生物科技有限公司 | Bifidobacterium breve and application thereof |
| CN112195122A (en) * | 2020-10-10 | 2021-01-08 | 内蒙古普泽生物制品有限责任公司 | Selenium-enriched animal bifidobacterium for inhibiting tumor growth and application thereof |
-
2021
- 2021-02-26 CN CN202110219055.1A patent/CN112807328B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599135A (en) * | 2013-10-30 | 2014-02-26 | 内蒙古双奇药业股份有限公司 | Solid-phase microecology preparation used for treating alcoholic liver injuries, and preparation method thereof |
| JP2018118915A (en) * | 2017-01-24 | 2018-08-02 | 雪印メグミルク株式会社 | Non-alcoholic liver injury inhibitor |
| CN109486715A (en) * | 2018-12-07 | 2019-03-19 | 江苏靶标生物医药研究所有限公司 | A kind of selenium-rich bifidobacterium longum and its preparation method and application |
| CN109929773A (en) * | 2019-01-10 | 2019-06-25 | 江苏德禧生物科技有限公司 | One plant of Bifidobacterium that can be used for selenium-rich culturing and its activated protein and application |
| CN111996153A (en) * | 2020-09-18 | 2020-11-27 | 南京益瑞兰生物科技有限公司 | Bifidobacterium breve and application thereof |
| CN112195122A (en) * | 2020-10-10 | 2021-01-08 | 内蒙古普泽生物制品有限责任公司 | Selenium-enriched animal bifidobacterium for inhibiting tumor growth and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| 富硒双歧杆菌中硒的含量与形态研究;梁佳等;《食品科学》;20101231;121-124 * |
| 富硒胶囊对小鼠的免疫促进作用及辐射保护作用;马玲等;《中国食品卫生杂志》;20001231;3-5 * |
| 微量元素硒与肿瘤放疗的研究进展;王继等;《实用肿瘤杂志》;20191231;281 * |
| 放射性肝损伤的研究进展;江林宫等;《世界华人消化杂志》;20171231;1811-1815 * |
| 硒与肝损伤的研究进展;张琳等;《现代预防医学》;20201231;4218-4220 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112807328A (en) | 2021-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220233639A1 (en) | Polypeptide for use in the protection of oxygen sensitive gram-positive bacteria | |
| CN111560331B (en) | Lactobacillus paracasei and application thereof | |
| CN109419814B (en) | Application of paradisella gordonii to inhibition of fatty liver disease | |
| WO2020147532A1 (en) | Use of isolated rhodococcus ruber cell wall skeleton in preparation of medicament for treating human cervical precancerous lesions | |
| US6165515A (en) | Method for treatment of osteoporosis | |
| CN112915109B (en) | Application of lactobacillus plantarum DP189 in preparation of medicine for preventing and/or treating Alzheimer disease | |
| KR102173168B1 (en) | A composition for improving intestine function comprising genus Leuconostoc | |
| CN116211900B (en) | Microecological viable bacteria preparation for improving polycystic ovary syndrome, and preparation method and application thereof | |
| Turdiyev et al. | CHOLERETIC ACTIVITY OF RUTANA AT THERAPEUTIC APPLICATION IN RATS WITH HELIOTRIN HEPATITIS | |
| Jia et al. | Dopamine-derived nanoparticles for the protection of irradiation-induced intestinal injury by maintaining intestinal homeostasis | |
| CN117106679A (en) | Probiotic agent for relieving insulin resistance and application thereof | |
| CN117286077B (en) | Probiotics for preventing and treating acute radioactive intestinal injury and application thereof | |
| CN114854638A (en) | Lactobacillus paracasei for relieving colitis by efficiently expressing adenosine deaminase | |
| JP4556009B2 (en) | Anti-inflammatory agents, preventive or ameliorating agents for allergic diseases and functional foods | |
| CN112807328B (en) | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury | |
| CN117568231A (en) | Lactobacillus johnsonii BW002 and application thereof in preventing and/or repairing liver injury | |
| US8858954B2 (en) | Pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease | |
| CN112353792A (en) | Application of eupatilin in preparing medicament for preventing or treating alcoholic liver disease | |
| CN117045687A (en) | Application of bacillus coagulans in preparation of medicine for preventing and treating intestinal injury caused by ionizing radiation | |
| WO2005077390A1 (en) | Hypoglycemic agent, remedy/preventive for diabetes and proces for producing the same | |
| CN112807438A (en) | Combined medicine composition for type 2 diabetes and liver injury and application thereof | |
| CN111803481A (en) | Application of L-alanine in preparing medicine for preventing and treating tuberculosis | |
| US11617729B2 (en) | Uses of guanidine hydrochloride as a drug for treating cancers/tumors | |
| CN105395584B (en) | The application of Pien Tze Huang and its preparation in the drug of preparation treatment multiple sclerosis | |
| JP2013056851A (en) | Type ii alveolar epithelial cell activator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240620 Address after: 215533 No.188 Wuyishan Road, Changshu hi tech Industrial Development Zone, Suzhou City, Jiangsu Province Patentee after: JIANGSU DAYSEBIOTECH Ltd. Country or region after: China Address before: 215533 No.188 Wuyishan Road, Changshu hi tech Industrial Development Zone, Suzhou City, Jiangsu Province Patentee before: JIANGSU DAYSEBIOTECH Ltd. Country or region before: China Patentee before: SHANGHAI JIAO TONG University |